Citigroup Inc. Sells 212,663 Shares of Zoetis Inc. $ZTS

Citigroup Inc. trimmed its position in Zoetis Inc. (NYSE:ZTS) by 24.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 672,386 shares of the company’s stock after selling 212,663 shares during the period. Citigroup Inc. owned 0.15% of Zoetis worth $98,384,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Rossby Financial LCC increased its holdings in Zoetis by 29.7% in the 3rd quarter. Rossby Financial LCC now owns 7,610 shares of the company’s stock worth $1,118,000 after purchasing an additional 1,744 shares in the last quarter. Stevens Capital Management LP grew its holdings in shares of Zoetis by 241.7% during the third quarter. Stevens Capital Management LP now owns 12,128 shares of the company’s stock worth $1,775,000 after purchasing an additional 8,579 shares during the last quarter. Isthmus Partners LLC increased its stake in shares of Zoetis by 1.6% in the third quarter. Isthmus Partners LLC now owns 71,493 shares of the company’s stock valued at $10,461,000 after buying an additional 1,093 shares during the period. Raiffeisen Bank International AG raised its holdings in Zoetis by 6.4% in the 3rd quarter. Raiffeisen Bank International AG now owns 204,311 shares of the company’s stock valued at $29,229,000 after buying an additional 12,228 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in Zoetis by 9.7% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 6,700 shares of the company’s stock valued at $980,000 after buying an additional 593 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $128.73 on Monday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $54.34 billion, a P/E ratio of 21.38, a P/E/G ratio of 1.97 and a beta of 0.96. The company has a fifty day moving average of $125.41 and a 200-day moving average of $134.64. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.00.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.6%. Zoetis’s dividend payout ratio is presently 35.22%.

Analyst Ratings Changes

Several brokerages have issued reports on ZTS. HSBC set a $140.00 price target on shares of Zoetis in a research report on Wednesday, December 10th. Bank of America raised their target price on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Stifel Nicolaus cut their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. UBS Group set a $136.00 price target on Zoetis in a research report on Thursday, January 29th. Finally, The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research report on Monday, December 15th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.